文献速递肝病消化道出血

肝硬化合并急性静脉曲张出血患者近二十年临床结局的改善

Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades.
PubMed 文献 · Gastrointest Endosc · 2025-05-03

该研究分析两家维也纳中心2000至2022年间406例肝硬化急性静脉曲张出血患者,发现6周内再出血率从19.4%降至11.8%(HR 0.59,95%CI 0.35-0.97,P=0.049),1年无移植生存率从63.8%升至73.7%(HR 0.68,95%CI 0.47-0.97,P=0.041),但出血相关死亡率从23.6%降至18.3%未达统计学显著(HR 0.68,95%CI 0.44-1.06,P=0.099)。

要点

  • 6周内再出血率从19.4%降至11.8%,HR 0.59(95%CI 0.35-0.97,P=0.049)。
  • 1年无移植生存率从63.8%升至73.7%,HR 0.68(95%CI 0.47-0.97,P=0.041)。
  • 出血相关死亡率从23.6%降至18.3%未达统计学显著(HR 0.68,95%CI 0.44-1.06,P=0.099)。

核心结论

  • 急性静脉曲张出血后再出血率和死亡率在过去二十年有所改善,但仍处于较高水平,需继续努力优化肝硬化患者结局。

研究设计与样本

  • 分析两家维也纳中心2000至2022年间406例肝硬化急性静脉曲张出血患者的数据,评估再出血、6周死亡率和1年无移植生存率。

主要发现

  • 6周内再出血率从19.4%降至11.8%(HR 0.59,95%CI 0.35-0.97,P=0.049)。
  • 出血相关死亡率从23.6%降至18.3%(HR 0.68,95%CI 0.44-1.06,P=0.099)。
  • 1年无移植生存率从63.8%升至73.7%(HR 0.68,95%CI 0.47-0.97,P=0.041)。
  • 较高的Child-Pugh评分与出血风险增加(aOR 1.68)和死亡率增加(aOR 1.69)相关,均P<0.001。
  • 非选择性β受体阻滞剂降低1年死亡风险(aOR 0.48,P=0.038)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Acute variceal bleeding (AVB), a severe adverse event of portal hypertension, may cause death in patients with cirrhosis. We investigated whether outcomes after AVB have improved over time. METHODS: Data from 406 patients with cirrhosis with AVB (2000-2022) from 2 Viennese centers were analyzed for recurrent bleeding, 6-week mortality, and 1-year transplant-free survival. RESULTS: Recurrent bleeding rates within 6 weeks decreased from 19.4% to 11.8% (hazard ratio [HR], 0.59; 95% CI, 0.35-0.97; P = .049) and bleeding-related mortality decreased from 23.6% to 18.3% (HR, 0.68; 95% CI, 0.44-1.06; P = .099). One-year transplant-free survival after AVB improved from 63.8% to 73.7% (HR, 0.68; 95% CI, 0.47-0.97; P = .041). Higher Child-Pugh scores were associated with increased risk for bleeding (adjusted odds ratio [aOR], 1.68) and mortality (aOR, 1.69; both P < .001). Nonselective beta-blockers reduced 1-year mortality risk (aOR, 0.48; P = .038). CONCLUSIONS: Recurrent bleeding and mortality rates after AVB improved over the last 2 decades but remain substantial, highlighting the need for continued efforts to optimize outcomes for patients with cirrhosis.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Pfisterer N, Riedl F, Schwarz M, et al. Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last 2 decades. Gastrointest Endosc. 2025. PMID: 40324727. doi:10.1016/j.gie.2025.04.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。